Posted in

How do liposomes improve the delivery of nucleic acids?

If you’ve ever followed biotech trends over the last decade, you’ve probably seen liposomes go from a niche lab trick to one of the most reliable tools for getting nucleic acids—think mRNA, siRNA, and plasmid DNA—into cells where they do their work. As a supplier focused on liposomal formulations, I’ve spent thousands of hours walking clients through why these tiny, fatty bubbles outperform every other delivery method out there, and it’s not just about one single trick. It’s a layered, practical solution that solves almost all the biggest headaches that come with nucleic acid delivery. Liposomal

Let’s start with the problem most new researchers and even biopharma teams trip over first: naked nucleic acids are terrible at surviving in the body. If you dump free mRNA or siRNA into a blood sample, within minutes, enzymes called nucleases will chew it into tiny, useless fragments. That’s not a lab-specific issue—it’s a biological fact. Nucleic acids are negatively charged, too, and cell membranes are also negatively charged, so they repel each other. A naked strand of siRNA can’t stick to a cell long enough to slip inside, let alone make its way through the cytoplasm and into the nucleus where DNA or mRNA needs to go. Early attempts at delivery relied on viral vectors, which worked for some applications but carried huge risks: immune reactions, insertional mutagenesis (where the virus jams its genetic material into the host’s DNA in the wrong place), and limited capacity for large nucleic acids. That’s where liposomes step in.

What makes liposomes unique is their structure. They’re spherical vesicles made of phospholipid bilayers—same stuff as cell membranes, so they’re basically tiny, cell-like bubbles. The key design here is that the inside of the vesicle is an aqueous core, perfect for holding water-soluble nucleic acids, while the outer surface is made of lipids that easily mix with fatty tissues and cell membranes. When we formulate a liposomal product, we load the nucleic acid into that aqueous core, and we can tweak the lipid composition to solve different problems. For example, adding cholesterol to the bilayer makes the membrane more stable, so the liposome doesn’t break apart before it reaches its target. Adding cationic lipids (positively charged) balances the negative charge of the nucleic acid, letting them bind tightly together inside the core, so they don’t leak out during transport. That’s the first big win: liposomes protect the nucleic acid from nucleases and the harsh environment of blood and tissue. I’ve had a client in a cancer research lab tell me that when they switched from naked siRNA to our liposomal formulation, their in vitro half-life jumped from 12 minutes to over 48 hours. That kind of difference is what moves a project from “interesting but unworkable” to “ready for preclinical trials.”

Next, liposomes fix the cell membrane repulsion problem. Because the outer lipid layer matches the cell’s own membrane, they fuse with it much more easily than free nucleic acids. Or, if the liposome is taken up by the cell via endocytosis (a process where cells wrap outside particles into a little bubble to bring them inside), we can adjust the pH of the liposome’s core to trigger the membrane to break down once inside. That’s called the “proton sponge effect,” and it’s one of the reasons liposomes are so good at releasing their cargo in the right place. When the endosome (the bubble the cell uses to take in the liposome) gets acidified, certain lipids in the liposome’s bilayer pull in protons and water, causing the endosome to swell and burst. The nucleic acid is then released into the cytoplasm, where it can do its job—something that doesn’t happen with naked nucleic acids, which usually get trapped and degraded in the endosome if they even get that far.

Another advantage that’s easy to overlook but makes a huge difference in real-world use: liposomes are versatile. We can modify their surface to target specific cell types, which cuts down on off-target effects—a massive concern for nucleic acid therapies. For example, adding a small protein fragment or a sugar molecule that binds to receptors only found on liver cells or cancer cells means the liposome will go straight to those cells instead of spreading all over the body and causing unwanted side effects. I worked with a rare disease research team a couple of years back that needed to deliver mRNA to lung epithelial cells; we modified our liposomes with a transferrin receptor ligand, and their in vivo delivery efficiency went up by a factor of seven, with almost no accumulation in the liver or spleen, which is where many non-targeted liposomes end up. That level of control isn’t something you get with viral vectors or even many polymer-based delivery systems.

Let’s talk about scalability, too, because no lab wants a delivery method that works in a petri dish but can’t be made in thousands of doses for a clinical trial. Liposomal formulations are built from phospholipids, which are abundant, FDA-excipient-compliant materials. The manufacturing processes for liposomes have been standardized over the past 30 years—from thin-film hydration to microfluidic mixing to size extrusion—so they can be scaled up without losing consistency. A lot of polymer-based carriers require custom synthesis or purification steps that don’t scale well, and viral vectors have their own manufacturing bottlenecks with cell culture and purification. For a biotech company that’s moving a product from preclinical to Phase 1 trials, being able to produce consistent, large batches of delivery agent is non-negotiable. As a supplier, that’s a big part of what we offer: we’ve optimized our manufacturing protocols to produce liposomes with uniform size (usually 80-150 nanometers, the sweet spot for cellular uptake and tissue penetration) and high loading efficiency, so clients don’t have to rework their formulation to meet regulatory or manufacturing needs.

Wait, let’s not gloss over the applications that have already transformed medicine, because that’s proof that liposome delivery works. The Pfizer and BioNTech and Moderna mRNA COVID vaccines are the most high-profile example, but they’re not the first—Doxil, a liposomal chemotherapy for cancer, has been on the market since the 1990s. More recently, siRNA therapies like Onpattro, which treats a rare nerve disorder, use liposomal delivery. That track record is critical because regulatory bodies (like the FDA and EMA) are much more willing to approve products that use a delivery method with a proven safety profile, rather than a brand-new technology with unknown risks. For nucleic acid therapies, which are already seen as inherently high-risk because they alter gene expression, having a delivery system that’s already been tested in millions of patients is a huge boost. We work closely with clients to make sure their liposomal formulations are compatible with regulatory guidelines, from raw material sourcing to stability testing, so they can get their products to patients faster.

Of course, liposomes aren’t perfect, but their limitations are the ones we’ve been solving for years. Early liposomes had issues with clearance by the reticuloendothelial system (RES)—a part of the immune system that traps foreign particles in the liver and spleen. We fixed that by adding PEG (polyethylene glycol) chains to the liposome surface; the PEG acts like a “stealth” coating, so the immune system doesn’t recognize the liposome as a foreign invader, letting it circulate longer in the body. We can also adjust the PEG coating to shed after the liposome reaches its target, which avoids the problem of PEG interfering with cellular uptake. Another challenge is loading efficiency: at first, liposomes could only hold a small amount of nucleic acid per vesicle, which meant you needed more material to get a therapeutic effect. Now, with our optimized cationic lipid blends, we can achieve loading efficiencies over 90% for many nucleic acid types, so every liposome has almost the maximum amount of cargo it can carry.

As a supplier, our job isn’t just to send liposome vials to a lab or a biotech company. It’s to help them tailor the formulation to their specific nucleic acid and use case. A researcher delivering plasmid DNA to muscle cells for a vaccine needs a different lipid composition than a clinician delivering siRNA to treat liver cancer, or a team delivering mRNA to edit genes ex vivo. We work with clients at every stage, from early lab-scale trials to late-stage preclinical development, to adjust size, surface modification, loading, and stability to meet their exact needs. We don’t just sell a product—we solve the problems that come with nucleic acid delivery, so our clients can focus on what they do best: developing therapies that change patients’ lives.

If you’re working on a nucleic acid project and you’re tired of fighting with low delivery efficiency, rapid cargo degradation, or off-target effects, we can help. Our team has decades of experience formulating liposomes for all types of nucleic acids, from small siRNA strands to large mRNA and plasmid DNA. We offer custom formulation development, scalable manufacturing, and regulatory support to get your product from the lab to the clinic. To learn more about how our liposomal delivery solutions can work for your project, get in touch to connect with our technical sales and formulation teams for a confidential discussion.

Anti-aging (Food) References

  1. Akbarzadeh, A., Rezaei-Sadabady, R., Davaran, S., Joo, S. W., Zarghami, N., Hanifehpour, Y., & Joo, S. W. (2013). Liposome: classification, preparation, and applications. Nanoscale research letters, 8(1), 102.
  2. Kulkarni, J. A., & Chen, X. (2018). Lipid nanoparticles for delivery of nucleic acids: a patent review. Expert opinion on therapeutic patents, 28(1), 1-14.
  3. Wang, Y., Liu, L., Han, L., & Zhang, N. (2020). Liposome-based nucleic acid delivery: a review of recent advances and clinical applications. Journal of Controlled Release, 325, 124-140.
  4. Allen, T. M., & Cullis, P. R. (2013). Liposomal drug delivery systems: from concept to clinical applications. Advanced drug delivery reviews, 65(1), 36-48.
  5. Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018). mRNA vaccines — a new era in vaccinology. Nature Reviews Drug Discovery, 17(4), 261-279.

Shaanxi Yuantai Biological Technology Co., Ltd.
Shaanxi Yuantai Biological Technology Co., Ltd. is one of the most professional liposomal manufacturers and suppliers in China, specialized in providing natural plant extracts with competitive price. We warmly welcome you to buy or wholesale bulk liposomal for sale here from our factory.
Address: NO.1 Plant, China Fnzyme Industrial Park, Economic Development Zone, Weinan City, Shaanxi, China
E-mail: sales@sxytbio.com
WebSite: https://www.sxytbio.com/